Executive Summary
Pluri Inc delivered a low-revenue quarter (Q3 2024 ended 2024-03-31) with a modest gross profit and a pronounced operating loss driven primarily by ongoing R&D and general-and-administrative expenses. Revenue of $71k produced a gross profit of $10k, yielding an EBITDA of approximately -$5.11m and a net loss of -$5.29m. The quarter underscored the company’s early-stage commercial profile: limited product revenue, substantial non-cash and cash burn characteristics, and a reliance on external funding to support its pipeline development. YoY revenue declined about 18.4% and QoQ revenue declined about 32.4%, highlighting a narrowed top line even as operating leverage remains negative due to high research and development spend and corporate expenses.
Key Performance Indicators
QoQ: -32.38% | YoY:-18.39%
QoQ: 100.20% | YoY:-88.51%
Key Insights
Revenue: $71,000 (YoY -18.39%, QoQ -32.38%). Gross Profit: $10,000, Gross Margin ≈ 14.08% (YoY -88.51%, QoQ +100.20%). Operating Income: -$5,534,000, Operating Margin ≈ -77.94% (YoY +22.06%, QoQ -6.16%). Net Income: -$5,293,000, Net Margin ≈ -74.55% (YoY +30.57%, QoQ -7.91%). EPS: -$1.01 (YoY +33.55%, QoQ -5.21%). Liquidity: Cash $7.35m; Short-term investments $18.93m; Total cash and short-term investments ≈ $26.28m; Net debt ≈ $22.73m; Total assets $36.39m; Total liabilities $34.55m; ...
Financial Highlights
Revenue: $71,000 (YoY -18.39%, QoQ -32.38%). Gross Profit: $10,000, Gross Margin ≈ 14.08% (YoY -88.51%, QoQ +100.20%). Operating Income: -$5,534,000, Operating Margin ≈ -77.94% (YoY +22.06%, QoQ -6.16%). Net Income: -$5,293,000, Net Margin ≈ -74.55% (YoY +30.57%, QoQ -7.91%). EPS: -$1.01 (YoY +33.55%, QoQ -5.21%). Liquidity: Cash $7.35m; Short-term investments $18.93m; Total cash and short-term investments ≈ $26.28m; Net debt ≈ $22.73m; Total assets $36.39m; Total liabilities $34.55m; Total stockholders’ equity ≈ -$0.36m. Cash flow: Net cash from operating activities -$4.20m; Net cash used in investing activities -$5.67m; Free cash flow ≈ -$4.29m. Current ratio 6.05; Debt profile: Long-term debt $29.41m; Total debt $30.08m; Net debt $22.73m. Revenue mix remains ultra-light, with R&D and G&A driving most Opex. Four-quarter trend shows 2024 Q3 revenue of $71k vs 2024 Q2 $105k and 2024 Q4 prior year $111k, reflecting a continued revenue cadence, not yet offset by scalable product sales.
Income Statement
| Metric |
Value |
YoY Change |
QoQ Change |
| Revenue |
71.00K |
-18.39% |
-32.38% |
| Gross Profit |
10.00K |
-88.51% |
100.20% |
| Operating Income |
-5.53M |
22.06% |
-6.16% |
| Net Income |
-5.29M |
30.57% |
-7.91% |
| EPS |
-1.01 |
33.55% |
-5.21% |
Key Financial Ratios
operatingProfitMargin
-7794%
operatingCashFlowPerShare
$-0.81
freeCashFlowPerShare
$-0.82
Management Commentary
Earnings call transcript data not provided in the dataset. As a result, management themes, qualitative guidance, and verbatim takeaways from the QQ3 2024 call could not be extracted from the supplied information. Investors should refer to the company’s official earnings release and transcript for management commentary on pipeline progress, strategic milestones, and any forward-looking statements.
Forward Guidance
No explicit forward guidance is disclosed in the provided data. Given the current quarterly profile—minimal top-line contribution, persistent R&D/G&A burn, and a leveraged balance sheet—near-term guidance would hinge on PLUR’s ability to advance PLXPAD (Phase III for muscle recovery post-hip fracture) and PLXR18, secure partnering or non-dilutive funding, and extend runway through working-capital management. In absence of stated targets, the assessment suggests monitoring: (1) upcoming clinical milestones and potential data readouts for PLXPAD/PLXR18; (2) any licensing or collaboration agreements; (3) capital-raising needs or financing terms; (4) changes in debt covenants or refinancing conditions. Achievability depends on pipeline momentum, regulatory clarity, and the company’s ability to execute partnerships or equity financing to extend its operating runway.